title: Late mortality in young BNLI patients cured of Hodgkin's disease.
abstract: A retrospective analysis was made of 1057 young patients (aged 15-29) with Hodgkin's disease (HD) who were entered into British National Lymphoma Investigation (BNLI) trials and studies between 1970 and 1992, and who had attained complete remission and remained disease-free thereafter from either their first-line (n = 774) or second-line (n = 283) treatment. Overall survivals at 20 years for those remaining disease-free from first-line and second-line treatment were 93% and 84%, respectively, compared to a survival of approximately 98.5% in the general population. In young patients cured by modern first-line therapeutic techniques, long-term survival should in future be only a little below that expected in the general population, and the emphasis of future trials should be directed towards the improvement of the efficacy of first-line treatment.
authors.affiliation: Department of Oncology, University College London Medical School, Middlesex Hospital, U.K.
authors.forename: B
authors.initials: B
authors.lastname: Vaughan Hudson
authors.forename: G
authors.initials: G
authors.lastname: Vaughan Hudson
authors.forename: D C
authors.initials: DC
authors.lastname: Linch
authors.forename: L
authors.initials: L
authors.lastname: Anderson
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002423:Cause of Death; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004739:England / Q000453:epidemiology; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy; D006801:Humans; D007239:Infections / Q000209:etiology / Q000401:mortality; D008017:Life Expectancy; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000401:mortality; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D013156:Splenectomy / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents